Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vilaprisan - Bayer HealthCare Pharmaceuticals

Drug Profile

Vilaprisan - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY 1002670; Bayer-sPRM; S-PRAnt; S-PRM; sPRM

Latest Information Update: 14 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Antineoplastics; Antiprogestogens; Infertility therapies; Small molecules; Sulfones
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uterine leiomyoma
  • Phase II Endometriosis

Most Recent Events

  • 26 Nov 2020 Bayer terminates phase II trial in Endometriosis in Austria, Canada, Czech Republic, Denmark, Serbia, Spain, Germany, Hungary, Bulgaria, Japan, Poland, Italy, Finland and USA (PO) (NCT03573336)
  • 15 Oct 2020 Bayer HealthCare Pharmaceuticals completes a phase II trial in Endometriosis in Austria, Bulgaria, Canada, Czech Republic, Denmark, Finland, Germany, Italy, Serbia, Spain, Hungary, Japan, Poland and USA (PO)(EudraCT2013-004768-72) (NCT03573336)
  • 14 Oct 2020 Bayer terminates phase I trial in Uterine leiomyoma in United Kingdom due to findings in the preclinical carcinogenicity studies for vilaprisan (PO) (NCT03342859)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top